Tryptophan for Sleep and Melatonin

Tryptophan is the chemical raw material for melatonin, the body's master circadian hormone. The pathway is short but tightly regulated: dietary L-tryptophan crosses the blood-brain barrier, is hydroxylated to 5-hydroxytryptophan (5-HTP), decarboxylated to serotonin, and then in the pineal gland is acetylated by AANAT and methylated by HIOMT to yield melatonin — with the AANAT step gated by darkness through a sympathetic-norepinephrine signal from the suprachiasmatic nucleus. Three supplement choices feed into this pathway at three different points (L-tryptophan, 5-HTP, exogenous melatonin), each with distinct kinetics, metabolic side-effects, and clinical use cases. This page also covers the 1989 L-tryptophan eosinophilia-myalgia syndrome (EMS) epidemic — the most consequential supplement-safety disaster in modern American regulatory history — the Showa Denko fermentation-contamination cause that was eventually identified, and why L-tryptophan returned to OTC sale after 2001 and is considered safe at therapeutic doses today.

Table of Contents

  1. The Tryptophan-to-Melatonin Pathway in One Diagram
  2. AANAT and HIOMT — The Pineal-Gating Enzymes
  3. Why Darkness Matters — The SCN-Norepinephrine-AANAT Axis
  4. Three Supplement Choices: L-Tryptophan vs 5-HTP vs Melatonin
  5. When to Use Which
  6. The 1989 L-Tryptophan EMS Epidemic
  7. The Showa Denko Contamination Cause
  8. The Quiet Return After 2001
  9. Modern L-Tryptophan Supplement Safety
  10. Cautions and Drug Interactions
  11. Key Research Papers
  12. Connections

The Tryptophan-to-Melatonin Pathway in One Diagram

The five-enzyme path from dietary tryptophan to circulating melatonin is one of the most elegant biochemical sequences in human physiology. Each step requires a specific enzyme, and each enzyme is subject to a different regulatory signal:

  1. L-tryptophan (dietary, plasma free fraction) crosses the blood-brain barrier via the LAT1 large neutral amino acid transporter, competing with leucine, isoleucine, valine, tyrosine, and phenylalanine for the same carrier protein.
  2. Tryptophan hydroxylase 2 (TPH2) adds a hydroxyl to position 5 of the indole ring, producing 5-hydroxytryptophan (5-HTP). This is the rate-limiting step of the whole pathway. TPH2 requires tetrahydrobiopterin (BH4), iron, and molecular oxygen as cofactors.
  3. Aromatic L-amino acid decarboxylase (AADC, also called DOPA decarboxylase) removes the carboxyl group to yield serotonin (5-hydroxytryptamine, 5-HT). AADC requires pyridoxal-5-phosphate (the active form of vitamin B6).
  4. Arylalkylamine N-acetyltransferase (AANAT) — expressed at high levels only in the pineal gland and retina — adds an acetyl group to the primary amine to yield N-acetylserotonin (NAS). AANAT activity is suppressed by light and induced by darkness via the SCN-norepinephrine axis described below. NAS itself has biological activity (TrkB receptor agonist; recently studied as a fast-acting antidepressant candidate).
  5. Hydroxyindole-O-methyltransferase (HIOMT, also called ASMT) methylates the 5-hydroxyl group using S-adenosylmethionine (SAMe) as methyl donor to yield melatonin (N-acetyl-5-methoxytryptamine), which is released directly into the bloodstream and CSF.

The bottleneck is AANAT. Its activity fluctuates roughly 100-fold across the day-night cycle, with peak activity in the middle of the biological night. Everything downstream of AANAT, including circulating melatonin, follows that 100-fold rhythm. The other four enzymes maintain relatively constant activity throughout the day.

Back to Table of Contents

AANAT and HIOMT — The Pineal-Gating Enzymes

AANAT is the keystone of melatonin biology. It is rapidly induced at the protein level by sympathetic norepinephrine signals to the pinealocyte after dark onset, and it is just as rapidly degraded by proteasomal pathways when light returns. The half-life of AANAT protein in the pineal is on the order of three to seven minutes — one of the shortest of any well-characterized enzyme. This short half-life is the molecular basis for the sharp on-off pattern of nighttime melatonin release.

HIOMT (also known by its gene symbol ASMT) operates downstream of AANAT and is constitutively expressed throughout the day. It is not the rate-limiting step under normal physiology. ASMT loss-of-function mutations have been associated with autism spectrum disorder in some studies, with the hypothesis being that low pineal melatonin output disrupts circadian-system development — though the genetic association has been inconsistent.

The pineal gland itself is unusual in being a circumventricular organ. It sits outside the blood-brain barrier and releases melatonin directly into the systemic circulation. This is why exogenous melatonin taken orally can effectively mimic endogenous output — it does not need to cross the BBB to act on the suprachiasmatic nucleus or any other CNS target. Both endogenous and exogenous melatonin act at MT1 and MT2 G-protein-coupled receptors expressed throughout the brain, the retina, the gut, and the vasculature.

Back to Table of Contents

Why Darkness Matters — The SCN-Norepinephrine-AANAT Axis

Pineal AANAT does not "know" it is night by sensing darkness directly. Instead, it receives a sympathetic norepinephrine signal that originates in the suprachiasmatic nucleus (SCN) of the hypothalamus, the master circadian clock. The SCN gets its light input from a specialized population of intrinsically photosensitive retinal ganglion cells (ipRGCs) expressing the photopigment melanopsin. When melanopsin detects blue-wavelength light (peak sensitivity around 480 nm), it signals the SCN to suppress its downstream output.

The pathway from SCN to pineal is multi-synaptic: SCN → paraventricular nucleus of the hypothalamus → intermediolateral cell column of the spinal cord → superior cervical ganglion → postganglionic sympathetic fibers releasing norepinephrine onto pineal beta-1 adrenergic receptors. Activation of beta-1 raises pineal cAMP, which induces AANAT transcription and stabilizes the protein against proteasomal degradation.

The practical implication is that any blue-spectrum light exposure in the evening suppresses melatonin release, even at modest intensities (as low as 30 lux can produce measurable suppression in sensitive individuals; 1000 lux suppresses essentially completely). Phone screens, laptop screens, LED household lighting, and even bright bathroom lighting can all delay the melatonin onset by hours if used in the pre-bedtime window. This is why blue-blocking glasses worn 2–3 hours before bed have measurable effects on sleep onset latency, even when subjects do not change any other behavior. It is also why nighttime work and rotating shift work produce such severe circadian disruption — the body literally cannot manufacture melatonin while the pineal is being commanded by bright light to suppress AANAT.

Back to Table of Contents

Three Supplement Choices: L-Tryptophan vs 5-HTP vs Melatonin

All three feed the same pathway but at different points. Their kinetics, metabolic distribution, and clinical effects differ in important ways:

L-Tryptophan

Native dietary amino acid. Enters the full distribution: gets used for protein synthesis, kynurenine catabolism (~95%), and serotonin/melatonin synthesis (~5%). This means the dose-response is shallow — doubling the dose does not double serotonin or melatonin output. Typical OTC dose is 500–2000 mg taken 30–60 minutes before bed, ideally with a small carbohydrate to leverage the insulin-BCAA-clearance trick. Onset of effect on subjective sleepiness is gradual (45–90 minutes). The hangover risk is low — because the pathway is throughput-limited at TPH2 and AANAT, you cannot easily over-shoot melatonin to morning levels.

5-HTP (5-Hydroxytryptophan)

Commercial 5-HTP is extracted from the seeds of Griffonia simplicifolia, a West African leguminous shrub. Bypasses the TPH2 rate-limit and goes directly into AADC, so it produces a faster and steeper rise in serotonin than L-tryptophan. The catch is that 5-HTP is decarboxylated to serotonin by AADC peripherally as well as centrally, meaning some of the dose is converted in the gut and the liver and never reaches the brain. Peripheral serotonin can cause nausea and GI upset, especially at doses above 100 mg. Typical dose is 50–300 mg taken 30–45 minutes before bed. 5-HTP is also commonly combined with carbidopa (a peripheral AADC inhibitor) in research settings to force more 5-HTP across the BBB before peripheral conversion.

Exogenous Melatonin

Skips the whole tryptophan pathway. Acts directly at MT1/MT2 receptors. Has the most rapid onset (30–60 minutes to peak plasma) and the most variable dosing recommendations — the long-running observation is that doses much smaller than commonly sold work just as well or better. 0.3 mg is often as effective as 3 mg or 10 mg for sleep-onset latency, and higher doses produce more next-day grogginess, more vivid dreams or nightmares, and more morning headache. The half-life is short (~30–45 minutes), so timed-release formulations are needed for sleep-maintenance insomnia. Common US OTC strengths (3 mg, 5 mg, 10 mg) are 10–30 times the physiologic peak.

Back to Table of Contents

When to Use Which

Each of the three has different clinical strengths:

For broader sleep hygiene strategies that should be addressed before or alongside any supplement, see Sleep Hygiene. For the diagnostic and management approach to chronic insomnia, see Insomnia.

Back to Table of Contents

The 1989 L-Tryptophan EMS Epidemic

In the fall of 1989, US clinicians began seeing patients with a strange new syndrome: severe muscle pain (myalgia), eosinophil counts in the blood above 1,000 cells per microliter (eosinophilia, normally less than 500), peripheral edema, skin rash, severe fatigue, and in some cases, scleroderma-like skin tightening, neuropathy, and pulmonary infiltrates. The condition came to be called eosinophilia-myalgia syndrome (EMS).

By November 1989, an epidemiologic case-control investigation in New Mexico had identified the common denominator: L-tryptophan supplements. The Centers for Disease Control issued an alert. By March 1990, over 1,500 cases had been reported across the United States. At least 37 patients died. Many survivors developed chronic disability with persistent neuromuscular pain, fatigue, and sometimes scleroderma-like skin changes that lasted years or decades.

The FDA responded by recalling L-tryptophan from the US market. By March 1990, L-tryptophan was effectively unavailable as a dietary supplement in the United States. The recall lasted, in practice, more than a decade.

The EMS outbreak became one of the most-cited cautionary tales in dietary supplement regulation. It was a major factor in the eventual passage of the 1994 Dietary Supplement Health and Education Act (DSHEA), which both expanded the supplement industry and gave the FDA limited tools to require adverse-event reporting. Even today, the EMS story is invoked whenever a new supplement-related adverse-event cluster is reported.

Back to Table of Contents

The Showa Denko Contamination Cause

The L-tryptophan molecule itself was not the problem. Epidemiologic and chemical investigations rapidly pointed to one specific manufacturer: Showa Denko K.K., a Japanese chemical company that produced 50–60% of the L-tryptophan sold in the United States during the relevant period. EMS cases were strongly clustered in patients who had consumed product traceable to Showa Denko lots. Other manufacturers' L-tryptophan had little or no excess risk.

Showa Denko had recently modified its bacterial fermentation production process for L-tryptophan, switching to a genetically engineered Bacillus amyloliquefaciens strain (Strain V) for higher yield and simultaneously reducing the powdered charcoal filtration step at the end of the process. The combination produced tryptophan with detectable contaminants present at the parts-per-million level. Chromatographic analysis of contaminated lots revealed two suspicious peaks subsequently called Peak 97 and Peak 200.

Peak 97 was identified as 1,1'-ethylidenebis-L-tryptophan (EBT), a dimer of two tryptophan molecules linked by an ethylidene bridge derived from acetaldehyde. Peak 200 and several other minor peaks were identified as related tryptophan condensation products. Multiple lines of evidence implicated EBT (and possibly other Peak X contaminants) as the proximate cause of EMS, though some researchers proposed that L-tryptophan itself might be capable of triggering EMS under conditions of unusually high intake combined with other susceptibility factors.

The Showa Denko company eventually paid more than $2 billion in settlements to EMS patients and admitted that its modified production process had introduced the contaminants. The factory was shut down and the relevant production strain destroyed. The case is now standard teaching material in pharmaceutical quality control, public health epidemiology, and biotechnology bioethics.

Back to Table of Contents

The Quiet Return After 2001

The FDA never formally banned L-tryptophan; it simply imposed an import alert that effectively prevented sale as a supplement in the US. In February 2001, FDA quietly lifted the import alert as long as manufacturers could demonstrate good manufacturing practices. By 2005, several brands of L-tryptophan were back on US retail shelves. By the 2010s, L-tryptophan was again widely available alongside 5-HTP and melatonin in the sleep-aid supplement category.

The return was deliberately quiet. There was no announcement, no consumer education campaign, and no formal FDA exoneration of L-tryptophan as a chemical entity. The implicit position was that L-tryptophan manufactured to modern bacterial-fermentation quality standards with appropriate purification is safe at typical supplement doses (500–2000 mg/day), and that the 1989–1990 outbreak was a manufacturing-defect incident specific to one contaminated production run from one supplier.

Two decades of post-return surveillance have supported that position. No EMS recurrence cluster has been associated with the modern L-tryptophan supply. The few isolated case reports of EMS-like syndromes since 2001 have not converged on any specific manufacturer or production batch. The current consensus in dietary-supplement pharmacovigilance is that L-tryptophan at therapeutic doses from reputable manufacturers carries no meaningful EMS risk.

Back to Table of Contents

Modern L-Tryptophan Supplement Safety

Modern L-tryptophan is produced by bacterial fermentation, typically using engineered strains of Escherichia coli or Corynebacterium glutamicum, with multi-step purification including activated charcoal filtration, ion exchange chromatography, and crystallization. Reputable manufacturers test for the specific EBT (Peak 97) marker and for related condensation products, and discard any batch above conservative limits.

From a consumer perspective, the practical safety advice is:

Back to Table of Contents

Cautions and Drug Interactions

Back to Table of Contents

Key Research Papers

  1. Hartmann E (1982). Effects of L-tryptophan on sleepiness and on sleep. Journal of Psychiatric Research 17:107–113. — PubMed
  2. Silber BY, Schmitt JA (2010). Effects of tryptophan loading on human cognition, mood, and sleep. Neuroscience & Biobehavioral Reviews 34:387–407. — PubMed
  3. Klein DC (2007). Arylalkylamine N-acetyltransferase: "the Timezyme." Journal of Biological Chemistry 282:4233–4237. — PubMed
  4. Brzezinski A et al. (2005). Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Medicine Reviews 9:41–50. — PubMed
  5. Auld F et al. (2017). Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders. Sleep Medicine Reviews 34:10–22. — PubMed
  6. Centers for Disease Control (1989). Eosinophilia-myalgia syndrome — New Mexico. MMWR 38:765–767. — PubMed
  7. Slutsker L et al. (1990). Eosinophilia-myalgia syndrome associated with exposure to tryptophan from a single manufacturer. JAMA 264:213–217. — PubMed
  8. Mayeno AN et al. (1990). Characterization of "Peak E", a novel amino acid associated with eosinophilia-myalgia syndrome. Science 250:1707–1708. — PubMed
  9. Belongia EA et al. (1990). An investigation of the cause of the eosinophilia-myalgia syndrome associated with tryptophan use. NEJM 323:357–365. — PubMed
  10. Klarskov K et al. (2018). Identification of 1,1'-ethylidenebis-tryptophan as a chemical marker for case-associated tryptophan in EMS. Toxicology Letters. — PubMed
  11. Allen JA et al. (2011). Post-epidemic eosinophilia-myalgia syndrome associated with L-tryptophan. Arthritis & Rheumatism 63:3633–3639. — PubMed
  12. Reiter RJ (1995). Functional pleiotropy of the neurohormone melatonin: antioxidant protection and neuroendocrine regulation. Frontiers in Neuroendocrinology. — PubMed

PubMed Topic Searches

Back to Table of Contents

Connections

Back to Table of Contents